Jonathan Yun, DO
Family Medicine · Murrieta, CANPI 1275572349
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 238 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 30 manufacturers reported payments, led by Abbott at 25.5% of the total. Among family medicine clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 238 payments — averaging $33.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- AstraZeneca$1K
- Lilly USA, LLC$1K
- Amgen$942
- Novo Nordisk$553
- Johnson & Johnson$301
- plus $2K from 24 others
Across 1 payment — averaging $1000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$1K
What the payments were for
- Food & beverage$7,939100%
- Education$170%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 27 | $2,025 |
| AstraZeneca | 40 | $1,222 |
| Lilly USA, LLC | 51 | $1,000 |
| Amgen | 19 | $942 |
| Novo Nordisk | 20 | $553 |
| Johnson & Johnson | 8 | $301 |
| Pfizer | 14 | $300 |
| Biohaven Pharmaceuticals, Inc. | 5 | $220 |
| GSK | 9 | $175 |
| Phathom Pharmaceuticals, Inc. | 4 | $174 |
| Hologic Sales And Service, LLC | 5 | $147 |
| Daiichi Sankyo Inc. | 1 | $125 |
| Vanda Pharmaceuticals Inc. | 4 | $103 |
| Amarin Pharma, Inc. | 4 | $89 |
| Mannkind Corporation | 4 | $81 |
| AbbVie | 3 | $70 |
| Medtronic(2 entities) | 3 | $55 |
| Edwards Lifesciences | 2 | $47 |
| Corcept Therapeutics | 2 | $39 |
| Exact Sciences | 2 | $36 |
| Boehringer Ingelheim | 1 | $32 |
| Astellas Pharma US Inc | 2 | $32 |
| UCB, Inc. | 1 | $32 |
| Hikma Pharmaceuticals USA | 1 | $25 |
| Eyevance Pharmaceuticals LLC | 1 | $25 |
| Neotract Inc. | 1 | $24 |
| Nestle Healthcare Nutrition Inc. | 1 | $24 |
| Ultragenyx Pharmaceutical Inc. | 1 | $22 |
| Si-bone, Inc. | 1 | $19 |
| Electromed, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PROCLAIM$513
- Proclaim IPG$492
- ETERNA$364
- BREZTRI$252
- Repatha$241
- Otezla$216
- INJECTAFER$125
- VOQUEZNA$125
- MOUNJARO$125
- XARELTO$125
- RYBELSUS$110
- AIRSUPRA$107
- NURTEC ODT$107
- Ozempic$102
How this compares
$7,955 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 229 | $260,393 |
| TrulicityDulaglutide | 143 | $167,915 |
| EliquisApixaban | 70 | $62,531 |
| JardianceEmpagliflozin | 27 | $39,751 |
| MounjaroTirzepatide | 32 | $35,353 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 43 | $28,501 |
| RybelsusSemaglutide | 15 | $25,743 |
| JanuviaSitagliptin Phosphate | 20 | $25,301 |
| FarxigaDapagliflozin Propanediol | 22 | $24,176 |
| CreonLipase/Protease/Amylase | 34 | $20,594 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 70 | $18,816 |
| Bydureon BciseExenatide Microspheres | 16 | $17,167 |
| Repatha SureclickEvolocumab | 23 | $14,647 |
| Atorvastatin Calcium | 973 | $10,473 |
| Breo ElliptaFluticasone/Vilanterol | 16 | $7,265 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $553 | $286,136244 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $1,000 | $203,268175 claims |
| PfizerEliquis | $300 | $62,53170 claims |
| Boehringer IngelheimJardiance | $32 | $39,75127 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $175 | $35,76659 claims |
| AstraZenecaFarxiga | $1,222 | $24,17622 claims |
| AbbVieCreon | $70 | $20,59434 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.
Other family medicine in Murrieta
- Bridget BriggsMurrieta$116K
- Sherly SoleimanEncino$1.2M
- Pamela KushnerLos Angeles$1.2M
- Sujata NarayanStanford$1.2M
- Jeffrey UngerChino$906K
- Alexander RivkinLos Angeles$866K
- Scott HowellLos Angeles$793K
- Derrick ButlerLos Angeles$692K
- Sandra CalmanMontara$589K
- Anthony JonesOakland$377K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.